Overview

A Phase 1, First-in-human Study of VX-634

Status:
Not yet recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of VX-634 at various doses.
Phase:
Phase 1
Details
Lead Sponsor:
Vertex Pharmaceuticals Incorporated